Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
in GA lesion growth versus control at 12 months (P Safety was reported as favorable across 45 subjects, with no treatment-related serious adverse events ; one case of mild intraocular inflammation resolved with standard management and CNV events were attributed to disease or procedure. Ocugen plans an optimized, adaptive Phase III (~300 patients, 95% power) focused on a 2.5–17.5 mm² lesion-size window and is targeting initiation of the global program in Q3 2026, pending regulatory alignment. Interested in Ocugen, Inc.? Here are five stocks we like better. Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a modifier gene therapy delivered via a single subretinal injection for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Executives and clinical investigators emphasized the unmet need in GA and positioned OCU410 as a potential alternative to currently approved complement inhibit
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Ocugen (OCGN) had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Ocugen (OCGN) Has A Healthy Cash Position For 2026 [Yahoo! Finance]Yahoo! Finance
- Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript [Seeking Alpha]Seeking Alpha
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswire
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/24/26 - Form 8-K
- 3/20/26 - Form 8-K
- 3/5/26 - Form 3
- OCGN's page on the SEC website